

# **Chapter 6**

## **References**

## 6 References

1. Junker, A., et al., *Extensive subpial cortical demyelination is specific to multiple sclerosis*. Brain Pathology, 2020. **30**(3): p. 641-652.
2. Prat, A. and J. Antel, *Pathogenesis of multiple sclerosis*. Current opinion in neurology, 2005. **18**(3): p. 225-230.
3. Schulze-Topphoff, U., et al., *Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2*. Proceedings of the National Academy of Sciences, 2016. **113**(17): p. 4777-4782.
4. Brady, S., *Basic neurochemistry: molecular, cellular and medical aspects*. 2005: Elsevier.
5. D'Aversa, T.G., et al., *Myelin basic protein induces inflammatory mediators from primary human endothelial cells and blood-brain barrier disruption: implications for the pathogenesis of multiple sclerosis*. Neuropathology and applied neurobiology, 2013. **39**(3): p. 270-283.
6. Mayo, L., F.J. Quintana, and H.L. Weiner, *The innate immune system in demyelinating disease*. Immunological reviews, 2012. **248**(1): p. 170-187.
7. Graça, D.L., et al., *Behaviour of oligodendrocytes and Schwann cells in an experimental model of toxic demyelination of the central nervous system*. Arquivos de neuro-psiquiatria, 2001. **59**: p. 358-361.
8. Foster, S.C., et al., *Dysregulation of the hypothalamic-pituitary-gonadal axis in experimental autoimmune encephalomyelitis and multiple sclerosis*. Journal of neuroimmunology, 2003. **140**(1-2): p. 78-87.
9. Calabrese, M., et al., *Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis*. Archives of neurology, 2007. **64**(10): p. 1416-1422.
10. Loma, I. and R. Heyman, *Multiple sclerosis: pathogenesis and treatment*. Current neuropharmacology, 2011. **9**(3): p. 409-416.
11. Sarchielli, P., et al., *Localized 1 H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis*. Journal of neurology, 2002. **249**(7): p. 902-910.
12. Miller, D.H. and S.M. Leary, *Primary-progressive multiple sclerosis*. The Lancet Neurology, 2007. **6**(10): p. 903-912.
13. Dutta, R. and B.D. Trapp, *Relapsing and progressive forms of multiple sclerosis—insights from pathology*. Current opinion in neurology, 2014. **27**(3): p. 271.
14. Walton, C., et al., *Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS*. Multiple Sclerosis Journal, 2020. **26**(14): p. 1816-1821.
15. Wallin, M.T., et al., *Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016*. The Lancet Neurology, 2019. **18**(3): p. 269-285.
16. Organization, W.H., *Multiple Sclerosis International Federation. Atlas of Multiple Sclerosis*. 2015.
17. Goyal, V., *Multiple sclerosis in India*. Annals of Indian Academy of Neurology, 2018. **21**(2): p. 95.
18. Veljkovic, E., et al., *Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases: Overview of Epidemiological Data on Smoking and Preclinical and Clinical Data on Nicotine*. 2018.

19. Ashley-Koch, A., Q. Yang, and R.S. Olney, *Sickle hemoglobin (Hb S) allele and sickle cell disease: a HuGE review*. American journal of epidemiology, 2000. **151**(9): p. 839-845.
20. Wootla, B., M. Eriguchi, and M. Rodriguez, *Is multiple sclerosis an autoimmune disease?* Autoimmune diseases, 2012. **2012**.
21. Ramagopalan, S.V., et al., *Multiple sclerosis: risk factors, prodromes, and potential causal pathways*. The Lancet Neurology, 2010. **9**(7): p. 727-739.
22. Motl, R.W., et al., *Does the relationship between physical activity and quality of life differ based on generic versus disease-targeted instruments?* Annals of Behavioral Medicine, 2008. **36**(1): p. 93-99.
23. McDonald, W.I., et al., *Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis*. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 2001. **50**(1): p. 121-127.
24. Inglese, M. and M. Petracca, *Imaging multiple sclerosis and other neurodegenerative diseases*. Prion, 2013. **7**(1): p. 47-54.
25. Simmons, D., *The use of animal models in studying genetic disease: transgenesis and induced mutation*. Nature education, 2008. **1**(1): p. 70.
26. Rivers, T.M., D. Sprunt, and G. Berry, *Observations on attempts to produce acute disseminated encephalomyelitis in monkeys*. The Journal of experimental medicine, 1933. **58**(1): p. 39.
27. Rivers, T.M. and F.F. Schwentker, *Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys*. The Journal of experimental medicine, 1935. **61**(5): p. 689-702.
28. Olitsky, P.K. and R.H. Yager, *Experimental disseminated encephalomyelitis in white mice*. The Journal of experimental medicine, 1949. **90**(3): p. 213-224.
29. McAlpine, D. and A. Compston, *McAlpine's multiple sclerosis*. 2005: Elsevier Health Sciences.
30. Bittner, S., et al., *Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice*. JoVE (Journal of Visualized Experiments), 2014(86): p. e51275.
31. Robinson, A.P., et al., *The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment*, in *Handbook of clinical neurology*. 2014, Elsevier. p. 173-189.
32. Oliver, A.R., G.M. Lyon, and N.H. Ruddle, *Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice*. The Journal of Immunology, 2003. **171**(1): p. 462-468.
33. Swanborg, R.H., *Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity*. Immunological reviews, 2001. **184**(1): p. 129-135.
34. Rivero, V.E., C.M. Riera, and G.A. Roth, *Humoral response against myelin antigens in two strains of rats with different susceptibility to experimental allergic encephalomyelitis (EAE)*. Autoimmunity, 1999. **29**(2): p. 129-137.
35. Chen, G.Q., et al., *Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats*. Brain research, 2010. **1309**: p. 116-125.
36. Wang, T., et al., *Chronic caffeine treatment protects against experimental autoimmune encephalomyelitis in mice: therapeutic window and receptor subtype mechanism*. Neuropharmacology, 2014. **86**: p. 203-211.

37. Sahrbacher, U.C., et al., *Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis*. European journal of immunology, 1998. **28**(4): p. 1332-1338.
38. Zorzella, S.F.G., et al., *Resistance to experimental autoimmune encephalomyelitis development in Lewis rats from a conventional animal facility*. Memórias Do Instituto Oswaldo Cruz, 2007. **102**(8): p. 931-936.
39. Sanai, S.A., et al., *Aging and multiple sclerosis*. Multiple Sclerosis Journal, 2016. **22**(6): p. 717-725.
40. Seamons, A., A. Perchellet, and J. Goverman, *Immune tolerance to myelin proteins*. Immunologic research, 2003. **28**(3): p. 201-221.
41. Martin, R., H.F. McFarland, and D.E. McFarlin, *Immunological aspects of demyelinating diseases*. Annual review of immunology, 1992. **10**(1): p. 153-187.
42. Bruno, R., et al., *Multiple sclerosis candidate autoantigens except myelin oligodendrocyte glycoprotein are transcribed in human thymus*. European journal of immunology, 2002. **32**(10): p. 2737-2747.
43. Zamvil, S., et al., *T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination*. Nature, 1985. **317**(6035): p. 355-358.
44. Iglesias, A., et al., *T-and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis*. Glia, 2001. **36**(2): p. 220-234.
45. Greer, J.M., *Autoimmune T-cell reactivity to myelin proteolipids and glycolipids in multiple sclerosis*. Multiple sclerosis international, 2013. **2013**.
46. Huang, L., et al., *Development of a chronic kidney disease model in C57BL/6 mice with relevance to human pathology*. Nephron extra, 2013. **3**(1): p. 12-29.
47. Ozgen, H., et al., *Oligodendroglial membrane dynamics in relation to myelin biogenesis*. Cellular and molecular life sciences, 2016. **73**(17): p. 3291-3310.
48. Burrows, D.J., et al., *Animal models of multiple sclerosis: from rodents to zebrafish*. Multiple Sclerosis Journal, 2019. **25**(3): p. 306-324.
49. Brown, A. and D. McFarlin, *Relapsing experimental allergic encephalomyelitis in the SJL/J mouse*. Laboratory investigation; a journal of technical methods and pathology, 1981. **45**(3): p. 278-284.
50. McRae, B.L., et al., *Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein*. Journal of neuroimmunology, 1992. **38**(3): p. 229-240.
51. Constantinescu, C.S. and B.A. Hilliard, *Adjuvants in EAE*, in *Experimental Models of Multiple Sclerosis*. 2005, Springer. p. 73-84.
52. Namer, I., et al., *The role of Mycobacterium tuberculosis in experimental allergic encephalomyelitis*. European neurology, 1994. **34**(4): p. 224-227.
53. Namer, I. and J. Steibel, *Antibody directed against mannan of the Mycobacterium tuberculosis cell envelope provokes blood-brain barrier breakdown*. Journal of neuroimmunology, 2000. **103**(1): p. 63-68.
54. Rabchevsky, A.G., J.-D. Degos, and P.A. Dreyfus, *Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis*. Brain research, 1999. **832**(1-2): p. 84-96.
55. Calida, D., et al., *Experimental allergic neuritis in the SJL/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12*. Journal of the Peripheral Nervous System, 2000. **5**(4): p. 247-247.

56. Lu, C., et al., *Endothelial histamine H1 receptor signaling reduces blood–brain barrier permeability and susceptibility to autoimmune encephalomyelitis*. Proceedings of the National Academy of Sciences, 2010. **107**(44): p. 18967-18972.
57. Ciabattini, A., et al., *Modulation of primary immune response by different vaccine adjuvants*. Frontiers in immunology, 2016. **7**: p. 427.
58. Goldenberg, M.M., *Multiple sclerosis review*. Pharmacy and therapeutics, 2012. **37**(3): p. 175.
59. Meissner, M., et al., *Dimethyl fumarate—only an anti-psoriatic medication?* JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2012. **10**(11): p. 793-801.
60. Cada, D.J., T.L. Levien, and D.E. Baker, *Dimethyl fumarate*. Hospital pharmacy, 2013. **48**(8): p. 668-679.
61. Lategan, T.W., et al., *Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™(Monomethyl Fumarate) or Tecfidera®(Dimethyl Fumarate)*. CNS drugs, 2021. **35**(5): p. 567-574.
62. Magesh, S., Y. Chen, and L. Hu, *Small molecule modulators of K eap1-Nrf2-ARE pathway as potential preventive and therapeutic agents*. Medicinal research reviews, 2012. **32**(4): p. 687-726.
63. Humphries, F., et al., *Succination inactivates gasdermin D and blocks pyroptosis*. Science, 2020. **369**(6511): p. 1633-1637.
64. Kornberg, M.D., et al., *Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity*. Science, 2018. **360**(6387): p. 449-453.
65. Bavaro, D.F., et al., *Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections*. Expert opinion on drug safety, 2020. **19**(7): p. 817-842.
66. Diaz, G.M., et al., *Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients*. Scientific reports, 2018. **8**(1): p. 1-13.
67. McCullough, T., et al., *Comparative Gastric Irritation of the Fumaric Acid Esters Dimethyl Fumarate (DMF) and XP23829 in Rat and Monkey (P01. 159)*. 2013, AAN Enterprises.
68. Mrowietz, U., et al., *Efficacy and safety of LAS 41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm®-and placebo-controlled trial (BRIDGE)*. British journal of dermatology, 2017. **176**(3): p. 615-623.
69. Linker, R.A. and R. Gold, *Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects*. Current neurology and neuroscience reports, 2013. **13**: p. 1-7.
70. Kawakami, T., et al., *Determination of dimethyl fumarate and other fumaric and maleic acid diesters in desiccants and consumer products in Japan*. Journal of Health Science, 2011. **57**(3): p. 236-244.
71. Turk, D., et al., *Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases*. The EMBO journal, 2001. **20**(23): p. 6570-6582.
72. Karimi-Jafari, M., et al., *Creating cocrystals: a review of pharmaceutical cocrystal preparation routes and applications*. Crystal Growth & Design, 2018. **18**(10): p. 6370-6387.

73. Guo, M., et al., *Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications*. *Acta Pharmaceutica Sinica B*, 2021. **11**(8): p. 2537-2564.
74. Kumar Bandaru, R., et al., *Recent Advances in Pharmaceutical Cocrystals: From Bench to Market*. 2021. **12**.
75. Blatnik, M., S.R. Thorpe, and J.W. Baynes, *Succination of proteins by fumarate: mechanism of inactivation of glyceraldehyde-3-phosphate dehydrogenase in diabetes*. *Annals of the New York Academy of Sciences*, 2008. **1126**: p. 272.
76. Furber, M., et al., *Cathepsin C inhibitors: property optimization and identification of a clinical candidate*. *Journal of medicinal chemistry*, 2014. **57**(6): p. 2357-2367.
77. Hoppmann, N., et al., *New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis*. *Brain*, 2015. **138**(4): p. 902-917.
78. Lucchinetti, C., et al., *Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination*. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*, 2000. **47**(6): p. 707-717.
79. Denic, A., et al., *Deletion of virus-specific T-cells enhances remyelination in a model of multiple sclerosis*. *Journal of neurology & translational neuroscience*, 2014. **2**(1).
80. Jurewicz, A., W.E. Biddison, and J.P. Antel, *MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes*. *The journal of immunology*, 1998. **160**(6): p. 3056-3059.
81. Neumann, H., et al., *Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases*. *Trends in neurosciences*, 2002. **25**(6): p. 313-319.
82. Bittner, S. and H. Wiendl, *Neuroimmunotherapies targeting T cells: from pathophysiology to therapeutic applications*. *Neurotherapeutics*, 2016. **13**(1): p. 4-19.
83. Hansel, T.T., et al., *The safety and side effects of monoclonal antibodies*. *Nature reviews Drug discovery*, 2010. **9**(4): p. 325-338.
84. Copeland, R.A., M.R. Harpel, and P.J. Tummino, *Targeting enzyme inhibitors in drug discovery*. *Expert opinion on therapeutic targets*, 2007. **11**(7): p. 967-978.
85. Perišić Nanut, M., et al., *Cysteine cathepsins as regulators of the cytotoxicity of NK and T cells*. *Frontiers in immunology*, 2014. **5**: p. 616.
86. Medana, I., et al., *Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity*. *The Journal of Immunology*, 2001. **167**(2): p. 674-681.
87. Velotti, F., et al., *Differential expression of granzyme A and granzyme B proteases and their secretion by fresh rat natural killer cells (NK) and lymphokine-activated killer cells with NK phenotype (LAK-NK)*. *European journal of immunology*, 1992. **22**(4): p. 1049-1053.
88. Smyth, M.J., M. McGuire, and K. Thia, *Expression of recombinant human granzyme B. A processing and activation role for dipeptidyl peptidase I*. *The Journal of Immunology*, 1995. **154**(12): p. 6299-6305.
89. Tran, T.V., et al., *Dipeptidyl peptidase I: importance of progranzyme activation sequences, other dipeptide sequences, and the N-terminal amino group of synthetic substrates for enzyme activity*. *Archives of biochemistry and biophysics*, 2002. **403**(2): p. 160-170.

90. Liang, J., et al., *Disinhibition of cathepsin C caused by cystatin F deficiency aggravates the demyelination in a cuprizone model*. *Frontiers in Molecular Neuroscience*, 2016. **9**: p. 152.
91. Durose, W.W., et al., *Cathepsin C modulates myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis*. *Journal of Neurochemistry*, 2019. **148**(3): p. 413-425.
92. Huseby, E.S., et al., *Pathogenic CD8 T cells in multiple sclerosis and its experimental models*. *Frontiers in immunology*, 2012. **3**: p. 64.
93. Mendel, I., N.K. de Rosbo, and A. Ben-Nun, *A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: Fine specificity and T cell receptor V $\beta$  expression of encephalitogenic T cells*. *European journal of immunology*, 1995. **25**(7): p. 1951-1959.
94. Bettini, M., K. Rosenthal, and B.D. Evavold, *Pathogenic MOG-reactive CD8+ T cells require MOG-reactive CD4+ T cells for sustained CNS inflammation during chronic EAE*. *Journal of neuroimmunology*, 2009. **213**(1-2): p. 60-68.
95. Schmidt, M.M. and R. Dringen, *Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione*. *Neurochemistry international*, 2010. **57**(4): p. 460-467.
96. Moharreh-Khiabani, D., et al., *Fumaric acid and its esters: an emerging treatment for multiple sclerosis*. *Current neuropharmacology*, 2009. **7**(1): p. 60-64.
97. Gold, R., R. Linker, and M. Stangel, *Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action*. *Clinical Immunology*, 2012. **142**(1): p. 44-48.
98. Bauer, R.A., *Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies*. *Drug discovery today*, 2015. **20**(9): p. 1061-1073.
99. Cane, D.E. and J.-K. Sohng, *Inhibition of glyceraldehyde-3-phosphate dehydrogenase by pentalenolactone: kinetic and mechanistic studies*. *Archives of biochemistry and biophysics*, 1989. **270**(1): p. 50-61.
100. Kumar, B., et al., *4, 6-Diphenylpyrimidine derivatives as dual inhibitors of monoamine oxidase and acetylcholinesterase for the treatment of Alzheimer's disease*. *ACS Chemical Neuroscience*, 2018. **10**(1): p. 252-265.
101. Hofstetter, H.H., C.L. Shive, and T.G. Forsthuber, *Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells*. *The Journal of Immunology*, 2002. **169**(1): p. 117-125.
102. Miyamura, S., et al., *Myelin Oligodendrocyte Glycoprotein 35-55 (MOG 35-55)-induced Experimental Autoimmune Encephalomyelitis: A Model of Chronic Multiple Sclerosis*. *Bio-protocol*, 2019. **9**(24).
103. Richner, M., et al., *Hydraulic extrusion of the spinal cord and isolation of dorsal root ganglia in rodents*. *JoVE (Journal of Visualized Experiments)*, 2017(119): p. e55226.
104. Johnson, D.A., et al., *The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis*. *Toxicological Sciences*, 2010. **114**(2): p. 237-246.
105. McCombe, P.A., J. Harness, and M. Pender, *Effects of cyclosporin A treatment on clinical course and inflammatory cell apoptosis in experimental autoimmune*

- encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein.* Journal of neuroimmunology, 1999. **97**(1-2): p. 60-69.
106. Ajami, B., et al., *Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool.* Nature neuroscience, 2011. **14**(9): p. 1142.
107. Atakpa, P., et al., *GPN does not release lysosomal Ca<sup>2+</sup> but evokes Ca<sup>2+</sup> release from the ER by increasing the cytosolic pH independently of cathepsin C.* Journal of cell science, 2019. **132**(3): p. jcs223883.
108. Hagn, M., V.R. Sutton, and J.A. Trapani, *A colorimetric assay that specifically measures Granzyme B proteolytic activity: hydrolysis of Boc-Ala-Ala-Asp-S-Bzl.* Journal of visualized experiments: JoVE, 2014(93).
109. Holdgate, G.A., T.D. Meek, and R.L. Grimley, *Mechanistic enzymology in drug discovery: a fresh perspective.* Nature reviews Drug discovery, 2018. **17**(2): p. 115-132.
110. Strelow, J.M., *A perspective on the kinetics of covalent and irreversible inhibition.* SLAS DISCOVERY: Advancing Life Sciences R&D, 2017. **22**(1): p. 3-20.
111. Werdenberg, D., et al., *Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters.* Biopharmaceutics & drug disposition, 2003. **24**(6): p. 259-273.
112. Paz, M.M., et al., *A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase.* Chemical research in toxicology, 2012. **25**(7): p. 1502-1511.
113. Branchaud, B.P. and B.E. Turner, *Galactose oxidase: Probing radical mechanism with ultrafast radical probe,* in *Methods in enzymology.* 2002, Academic Press Inc. p. 415-425.
114. Murugesan, N., et al., *Active induction of experimental autoimmune encephalomyelitis by MOG35-55 peptide immunization is associated with differential responses in separate compartments of the choroid plexus.* Fluids and Barriers of the CNS, 2012. **9**(1): p. 1-17.
115. Yadav, S.K., et al., *Dimethyl fumarate suppresses demyelination and axonal loss through reduction in pro-inflammatory macrophage-induced reactive astrocytes and complement C3 deposition.* Journal of Clinical Medicine, 2021. **10**(4): p. 857.
116. Sonobe, Y., et al., *Chronological changes of CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets in the experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis.* The Tohoku journal of experimental medicine, 2007. **213**(4): p. 329-339.
117. Wu, Q., et al., *Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1/Th17 and Th2 in multiple sclerosis patients.* The Journal of Immunology, 2017. **198**(8): p. 3069-3080.
118. Haile, Y., et al., *Granzyme B-inhibitor serpin3n induces neuroprotection in vitro and in vivo.* Journal of neuroinflammation, 2015. **12**(1): p. 1-10.
119. Meade, J.L., et al., *A family with Papillon-Lefevre syndrome reveals a requirement for cathepsin C in granzyme B activation and NK cell cytolytic activity.* Blood, 2006. **107**(9): p. 3665-3668.
120. Delwaide, P., J. Schoenen, and V. De Pasqua, *Lumbosacral spinal evoked potentials in patients with multiple sclerosis.* Neurology, 1985. **35**(2): p. 174-174.
121. Pei, W., et al., *Direct modulation of myelin-autoreactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells in EAE mice by a tolerogenic nanoparticle co-carrying myelin peptide-loaded*

- major histocompatibility complexes, CD47 and multiple regulatory molecules. *International Journal of Nanomedicine*, 2018. **13**: p. 3731.
122. Kuerten, S., et al., *MP4-and MOG: 35–55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum*. *Journal of neuroimmunology*, 2007. **189**(1-2): p. 31-40.
123. Kuhlmann, T., et al., *Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time*. *Brain*, 2002. **125**(10): p. 2202-2212.
124. Giuliani, F., et al., *Vulnerability of human neurons to T cell-mediated cytotoxicity*. *The Journal of Immunology*, 2003. **171**(1): p. 368-379.
125. Machado, T.C., et al., *Cocrystallization as a novel approach to enhance the transdermal administration of meloxicam*. *European Journal of Pharmaceutical Sciences*, 2018. **123**: p. 184-190.
126. Likhitha, U., et al., *Do hydrogen bonding and noncovalent interactions stabilize nicotinamide-picric acid cocrystal supramolecular assembly?* *Journal of Molecular Structure*, 2019.
127. Aakeröy, C.B., M.E. Fasulo, and J. Desper, *Cocrystal or salt: does it really matter?* *Molecular Pharmaceutics*, 2007. **4**(3): p. 317-322.
128. Cavanagh, K.L., C. Maheshwari, and N. Rodríguez-Hornedo, *Understanding the differences between cocrystal and salt aqueous solubilities*. *Journal of pharmaceutical sciences*, 2018. **107**(1): p. 113-120.
129. Cheney, M.L., et al., *Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics*. *Journal of pharmaceutical sciences*, 2011. **100**(6): p. 2172-2181.
130. Galetzka, C., et al., *Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose*. 2019, Google Patents.
131. Deeks, E.D., *Dimethyl fumarate: a review in relapsing-remitting MS*. *Drugs*, 2016. **76**(2): p. 243-254.
132. Landenberger, K.B., O. Bolton, and A.J. Matzger, *Two isostructural explosive cocrystals with significantly different thermodynamic stabilities*. *Angewandte Chemie*, 2013. **125**(25): p. 6596-6599.
133. Khajir, S., *Preparation and investigation on the stability of salt or cocrystal forms of valproic acid and carbamazepine*. 2020, Tabriz University of Medical Sciences, Faculty of Pharmacy.
134. Nechipadappu, S.K., V. Tekuri, and D.R. Trivedi, *Pharmaceutical co-crystal of flufenamic acid: synthesis and characterization of two novel drug-drug co-crystal*. *Journal of pharmaceutical sciences*, 2017. **106**(5): p. 1384-1390.
135. Lu, J. and S. Rohani, *Preparation and characterization of theophylline–nicotinamide cocrystal*. *Organic Process Research & Development*, 2009. **13**(6): p. 1269-1275.
136. Abdallah, D.M., *Nicotinamide alleviates indomethacin-induced gastric ulcers: a novel antiulcer agent*. *European journal of pharmacology*, 2010. **627**(1-3): p. 276-280.
137. Fücke, K., et al., *How good are the crystallisation methods for co-crystals? A comparative study of piroxicam*. *New Journal of Chemistry*, 2012. **36**(10): p. 1969-1977.
138. Mills, E.A., et al., *Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis*. *Frontiers in neurology*, 2018. **9**: p. 5.

139. Brück, J., et al., *A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis*. *Experimental dermatology*, 2018. **27**(6): p. 611-624.
140. Moharregg-Khiabani, D., et al., *Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse*. *PloS one*, 2010. **5**(7).
141. Fiedler, S.E., et al., *Analysis of IL-6, IL-1 $\beta$  and TNF- $\alpha$  production in monocytes isolated from multiple sclerosis patients treated with disease modifying drugs*. *Journal of systems and integrative neuroscience*, 2017. **3**(3).
142. Morris, G.M., et al., *AutoDock*. Automated docking of flexible ligands to receptor-User Guide, 2001.
143. Huey, R., G.M. Morris, and S. Forli, *Using AutoDock 4 and AutoDock vina with AutoDockTools: a tutorial*. The Scripps Research Institute Molecular Graphics Laboratory, 2012. **10550**: p. 92037.
144. Studio, D., *Discovery Studio*. Accelrys [2.1], 2008.
145. Ganeshpurkar, A., et al., *Computational binding study with  $\alpha 7$  nicotinic acetylcholine receptor of Anvylic-3288: an allosteric modulator*. *Molecular Simulation*, 2020. **46**(13): p. 975-986.
146. Le Grand, S., A.W. Götz, and R.C. Walker, *SPFP: Speed without compromise—A mixed precision model for GPU accelerated molecular dynamics simulations*. *Computer Physics Communications*, 2013. **184**(2): p. 374-380.
147. Gotz, A.W., et al., *Routine microsecond molecular dynamics simulations with AMBER on GPUs. 1. Generalized born*. *Journal of chemical theory and computation*, 2012. **8**(5): p. 1542-1555.
148. Salomon-Ferrer, R., et al., *Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald*. *Journal of chemical theory and computation*, 2013. **9**(9): p. 3878-3888.
149. Sarraguça, M.C., et al., *Real-time monitoring of cocrystallization processes by solvent evaporation: A near infrared study*. *European Journal of Pharmaceutical Sciences*, 2016. **90**: p. 76-84.
150. Kumar, S., *Pharmaceutical Cocrystals: An Overview*. *Indian Journal of Pharmaceutical Sciences*, 2018. **79**(6): p. 858-871.
151. Buanz, A.B., G.N. Parkinson, and S. Gaisford, *Characterization of carbamazepine-nicotinamide cocrystal polymorphs with rapid heating DSC and XRPD*. *Crystal Growth & Design*, 2011. **11**(4): p. 1177-1181.
152. Batisai, E., et al., *Melting point–solubility–structure correlations in multicomponent crystals containing fumaric or adipic acid*. *CrystEngComm*, 2014. **16**(43): p. 9992-9998.
153. Park, B., et al., *Emodin-nicotinamide (1: 2) cocrystal identified by thermal screening to improve emodin solubility*. *International journal of pharmaceutics*, 2019. **557**: p. 26-35.
154. Weast, R.C. and M.J. Astle, *CRC handbook of chemistry and physics, 64 edn*. CRC, Boca Raton, 1984.
155. Litjens, N.H., et al., *Pharmacokinetics of oral fumarates in healthy subjects*. *British journal of clinical pharmacology*, 2004. **58**(4): p. 429-432.
156. Fang, H., et al., *Granulocyte colony stimulating factor induces lipopolysaccharide (LPS) sensitization via upregulation of LPS binding protein in rat*. *PLoS One*, 2013. **8**(2): p. e56654.
157. Danieli, P.P., B. Ronchi, and C. Rossi, *Assessing the in vitro viability of bovine peripheral blood mononuclear cells (PBMCs): a comparison between the MTT (or XTT) and Trypan Blue Exclusion (TBE) test*. *ACTA NATURALIS SCIENTIA*, 2014. **1**: p. 58-61.

158. Jedrzejewski, T., et al., *Silver nanoparticles augment releasing of pyrogenic factors by blood cells stimulated with LPS*. Open Life Sciences, 2014. **9**(11): p. 1058-1067.
159. Noosud, J., et al., *In vitro and in vivo assessment of inhibitory effect of stevioside on pro-inflammatory cytokines*. Avicenna journal of phytomedicine, 2017. **7**(2): p. 101.
160. Chauhan, P.S., et al., *Intranasal curcumin regulates chronic asthma in mice by modulating NF- $\kappa$ B activation and MAPK signaling*. Phytomedicine, 2018. **51**: p. 29-38.
161. Alaimo, A., R.M. Gorjod, and M.L. Kotler, *The extrinsic and intrinsic apoptotic pathways are involved in manganese toxicity in rat astrocytoma C6 cells*. Neurochemistry international, 2011. **59**(2): p. 297-308.
162. Paliwal, P., D. Dash, and S. Krishnamurthy, *Pharmacokinetic study of piracetam in focal cerebral ischemic rats*. European journal of drug metabolism and pharmacokinetics, 2018. **43**(2): p. 205-213.
163. Gold, R., et al., *Incidence and mitigation of gastrointestinal events in patients with relapsing–remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)*. Therapeutic advances in neurological disorders, 2018. **11**: p. 1756286418768775.
164. Palte, M.J., et al., *Improving the gastrointestinal tolerability of fumaric acid esters: Early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 Study*. Advances in therapy, 2019. **36**(11): p. 3154-3165.
165. Wang, J.P., et al., *Delayed healing of acetic acid-induced gastric ulcers in rats by indomethacin*. Gastroenterology, 1989. **96**(2): p. 393-402.
166. Xue, Z., et al., *Protective effect of polysaccharides from Radix Hedysari on gastric ulcers induced by acetic acid in rats*. Food & function, 2019. **10**(7): p. 3965-3976.
167. Yang, X., et al., *Structure–immunomodulatory activity relationships of Hedysarum polysaccharides extracted by a method involving a complex enzyme combined with ultrasonication*. Food & function, 2019. **10**(2): p. 1146-1158.
168. Sastry, K., et al., *Spectrophotometric determination of serum nitrite and nitrate by copper–cadmium alloy*. Analytical biochemistry, 2002. **306**(1): p. 79-82.
169. Rodríguez, J.A., L. Astudillo, and G. Schmeda-Hirschmann, *Oleanolic acid promotes healing of acetic acid-induced chronic gastric lesions in rats*. Pharmacological Research, 2003. **48**(3): p. 291-294.
170. Cadden, J., et al., *Cocrystal Formulations: Evaluation of the Impact of Excipients on Dissolution by Molecular Simulation and Experimental Approaches*. Crystal Growth & Design, 2021. **21**(2): p. 1006-1018.
171. Cuadra, I.A., et al., *Pharmaceutical co-crystals of the anti-inflammatory drug diflunisal and nicotinamide obtained using supercritical CO<sub>2</sub> as an antisolvent*. Journal of CO<sub>2</sub> Utilization, 2016. **13**: p. 29-37.
172. Ervasti, T., J. Aaltonen, and J. Ketolainen, *Theophylline–nicotinamide cocrystal formation in physical mixture during storage*. International journal of pharmaceuticals, 2015. **486**(1-2): p. 121-130.
173. Prasad, K.D., et al., *Effect of inductive effect on the formation of cocrystals and eutectics*. CrystEngComm, 2014. **16**(42): p. 9930-9938.
174. Shen, J.P., et al., *Preparation and characterization of a novel cocrystal explosive*. Crystal growth & design, 2011. **11**(5): p. 1759-1765.

175. Perpétuo, G., et al., *A combined approach using differential scanning calorimetry with polarized light thermomicroscopy in the investigation of ketoprofen and nicotinamide cocrystal*. *Thermochimica Acta*, 2017. **651**: p. 1-10.
176. Abdelrahman, R.S. and N. Abdel-Rahman, *Dimethyl fumarate ameliorates acetaminophen-induced hepatic injury in mice dependent of Nrf-2/HO-1 pathway*. *Life sciences*, 2019. **217**: p. 251-260.
177. Wilms, H., et al., *Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1 $\beta$ , TNF- $\alpha$  and IL-6 in an in-vitro model of brain inflammation*. *Journal of neuroinflammation*, 2010. **7**(1): p. 1-8.
178. Ungerstedt, J., M. Blombäck, and T. Söderström, *Nicotinamide is a potent inhibitor of proinflammatory cytokines*. *Clinical & Experimental Immunology*, 2003. **131**(1): p. 48-52.
179. Heeba, G.H., M.K. Hassan, and R.S. Amin, *Gastroprotective effect of simvastatin against indomethacin-induced gastric ulcer in rats: role of nitric oxide and prostaglandins*. *European journal of pharmacology*, 2009. **607**(1-3): p. 188-193.
180. Rocha, B.S., et al., *Role of nitrite, urate and pepsin in the gastroprotective effects of saliva*. *Redox biology*, 2016. **8**: p. 407-414.
181. Palmer, R.M. and S. Moncada, *A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells*. *Biochemical and biophysical research communications*, 1989. **158**(1): p. 348-352.
182. Kumar, P., et al., *Enhanced brain delivery of dimethyl fumarate employing tocopherol-acetate-based nanolipidic carriers: evidence from pharmacokinetic, biodistribution, and cellular uptake studies*. *ACS chemical neuroscience*, 2017. **8**(4): p. 860-865.
183. Dyakonov, T., S. Agnihotri, and A.A. Fatmi, *Controlled release fumarate esters*. 2016, Google Patents.
184. Kumar, S. and A. Nanda, *Approaches to Design of Pharmaceutical Cocrystals: A Review*. *Molecular Crystals and Liquid Crystals*, 2018. **667**(1): p. 54-77.
185. Yan, Y., J.-M. Chen, and T.-B. Lu, *Simultaneously enhancing the solubility and permeability of acyclovir by crystal engineering approach*. *CrystEngComm*, 2013. **15**(33): p. 6457-6460.
186. Elbagerma, M., et al., *Identification of a new cocrystal of citric acid and paracetamol of pharmaceutical relevance*. *CrystEngComm*, 2011. **13**(6): p. 1877-1884.
187. Ober, C.A. and R.B. Gupta, *Formation of itraconazole–succinic acid cocrystals by gas antisolvent cocrystallization*. *Aaps Pharmscitech*, 2012. **13**(4): p. 1396-1406.
188. SUGIMOTO, I., A. KUCHIKI, and H. NAKAGAWA, *Stability of nifedipine-polyvinylpyrrolidone coprecipitate*. *Chemical and Pharmaceutical Bulletin*, 1981. **29**(6): p. 1715-1723.
189. Adeshina, Y.O., E.J. Deeds, and J. Karanicolas, *Machine learning classification can reduce false positives in structure-based virtual screening*. *Proceedings of the National Academy of Sciences*, 2020. **117**(31): p. 18477-18488.
190. Lu, E., N. Rodríguez-Hornedo, and R. Suryanarayanan, *A rapid thermal method for cocrystal screening*. *CrystEngComm*, 2008. **10**(6): p. 665-668.
191. Silverstein, R.M. and G.C. Bassler, *Spectrometric identification of organic compounds*. *Journal of Chemical Education*, 1962. **39**(11): p. 546.

192. Scerba, M.T., et al., *Characterization of Highly Unusual NH<sup>+</sup>–O Hydrogen Bonding to Ester Ether Oxygen Atoms through Spectroscopic and Computational Studies*. The Journal of Physical Chemistry A, 2012. **116**(14): p. 3556-3560.
193. Zhang, T., et al., *Preparation of 2: 1 urea-succinic acid cocrystals by sublimation*. Journal of Crystal Growth, 2017. **469**: p. 114-118.
194. Sarkar, A. and S. Rohani, *Cocrystals of acyclovir with promising physicochemical properties*. Journal of pharmaceutical sciences, 2015. **104**(1): p. 98-105.
195. Thakur, S., et al., *Enhancement of Microwave Absorption Properties of Epoxy by Sol–Gel-Synthesised ZnO Nanoparticles*. Indian Chemical Engineer, 2016. **58**(4): p. 310-324.
196. Jung, S., J.-M. Ha, and I. Kim, *Phase transformation of adefovir dipivoxil/succinic acid cocrystals regulated by polymeric additives*. Polymers, 2014. **6**(1): p. 1-11.
197. Karagianni, A., M. Malamataris, and K. Kachrimanis, *Pharmaceutical cocrystals: new solid phase modification approaches for the formulation of APIs*. Pharmaceutics, 2018. **10**(1): p. 18.
198. Bogner, E., et al., *Antioxidant and anti-inflammatory effects in RAW264. 7 macrophages of malvidin, a major red wine polyphenol*. PloS one, 2013. **8**(6).
199. McGuire, V.A., et al., *Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation*. Scientific reports, 2016. **6**: p. 31159.
200. Gerhardt, S., et al., *Dimethylfumarate protects against TNF- $\alpha$ -induced secretion of inflammatory cytokines in human endothelial cells*. Journal of Inflammation, 2015. **12**(1): p. 49.
201. Al-Otaibi, J.S., et al., *Cocrystals of pyrazinamide with p-toluenesulfonic and ferulic acids: DFT investigations and molecular docking studies*. Journal of Molecular Structure, 2019. **1175**: p. 916-926.
202. Kufareva, I. and R. Abagyan, *Methods of protein structure comparison, in Homology modeling*. 2011, Springer. p. 231-257.
203. Fatriansyah, J.F., et al., *Molecular docking and dynamics studies on propolis sulabiroidin-A as a potential inhibitor of SARS-CoV-2*. Journal of King Saud University-Science, 2022. **34**(1): p. 101707.
204. Allu, S., et al., *Role of hydrogen bonding in cocrystals and coamorphous solids: indapamide as a case study*. CrystEngComm, 2019. **21**(13): p. 2043-2048.
205. Jayasankar, A., et al., *Cocrystal formation during cogrinding and storage is mediated by amorphous phase*. Pharmaceutical research, 2006. **23**(10): p. 2381-2392.
206. Cao, Y. and T. Mu, *Comprehensive investigation on the thermal stability of 66 ionic liquids by thermogravimetric analysis*. Industrial & engineering chemistry research, 2014. **53**(20): p. 8651-8664.
207. Saganowska, P. and M. Wesolowski, *DSC as a screening tool for rapid co-crystal detection in binary mixtures of benzodiazepines with co-formers*. Journal of Thermal Analysis and Calorimetry, 2018. **133**(1): p. 785-795.
208. Chadha, R., et al., *Preparation and solid-state characterization of three novel multicomponent solid forms of oxcarbazepine: improvement in solubility through saccharin cocrystal*. Crystal Growth & Design, 2012. **12**(8): p. 4211-4224.
209. Chen, A.M., et al., *Development of a pharmaceutical cocrystal of a monophosphate salt with phosphoric acid*. Chemical communications, 2007(4): p. 419-421.

210. Maheshwari, C., et al., *Tailoring aqueous solubility of a highly soluble compound via cocrystallization: effect of coformer ionization, pH max and solute–solvent interactions*. CrystEngComm, 2012. **14**(14): p. 4801-4811.
211. Xue, N., et al., *The mechanism of binding with the  $\alpha$ -glucosidase in vitro and the evaluation on hypoglycemic effect in vivo: Cocrystals involving synergism of gallic acid and conformer*. European Journal of Pharmaceutics and Biopharmaceutics, 2020. **156**: p. 64-74.
212. Jing, X., et al., *Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity*. Neuroscience, 2015. **286**: p. 131-140.
213. Ye, K.Y., T. Yastreb, and N. Miroshnichenko, *Influence of salicylic and succinic acids on antioxidant enzymes activity, heat resistance and productivity of Panicum miliaceum L.* Journal of Stress Physiology & Biochemistry, 2011. **7**(2): p. 154-163.

#### **List of publications from thesis:**

- ❖ **Qadir Alam**, Sairam Krishnamurthy “Novel Gastroprotective and Thermostable Cocrystal of Dimethyl fumarate: its Preparation, Characterization, in-vitro and in-vivo Evaluation”, *ACS Omega*, DOI 10.1021/acsomega.3c02463.
- ❖ **Qadir Alam**, and Sairam Krishnamurthy "Preparation, characterization, in-vitro and in-vivo pharmacokinetic evaluation of thermostable dimethyl fumarate cocrystals" *Journal of Pharmaceutical Sciences*.

#### **List of publications during Ph.D.**

- ❖ **Alam, Qadir**, and Sairam Krishnamurthy. "Dihydroquercetin ameliorates LPS-induced neuroinflammation and memory deficit." *Current Research in Pharmacology and Drug Discovery* 3 (2022): 100091.
- ❖ Ganeshpurkar, A., Singh, R., Tripathi, P., **Alam, Q.**, Krishnamurthy, S., Kumar, A., & Singh, S. K. (2023). Effect of sulfonamide derivatives of phenylglycine on scopolamine-induced amnesia in rats. *Ibrain*, 9(1), 13-31.